Literature DB >> 28748367

Commercial Online Social Network Data and Statin Side-Effect Surveillance: A Pilot Observational Study of Aggregate Mentions on Facebook.

Marco D Huesch1,2.   

Abstract

INTRODUCTION: Surveillance of the safety of prescribed drugs after marketing approval has been secured remains fraught with complications. Formal ascertainment by providers and reporting to adverse-event registries, formal surveys by manufacturers, and mining of electronic medical records are all well-known approaches with varying degrees of difficulty, cost, and success. Novel approaches may be a useful adjunct, especially approaches that mine or sample internet-based methods such as online social networks.
METHODS: A novel commercial software-as-a-service data-mining product supplied by Sysomos from Datasift/Facebook was used to mine all mentions on Facebook of statins and stain-related side effects in the US in the 1-month period 9 January 2017 through 8 February 2017.
RESULTS: A total of 4.3% of all 25,700 mentions of statins also mentioned typical stain-related side effects. Multiple methodological weaknesses stymie interpretation of this percentage, which is however not inconsistent with estimates that 5-20% of patients taking statins will experience typical side effects at some time.
CONCLUSIONS: Future work on pharmacovigilance may be informed by this novel commercial tool, but the inability to mine the full text of a posting poses serious challenges to content categorization.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28748367     DOI: 10.1007/s40264-017-0577-3

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  2 in total

1.  Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.

Authors:  Andrzej Jarynowski; Alexander Semenov; Mikołaj Kamiński; Vitaly Belik
Journal:  J Med Internet Res       Date:  2021-11-29       Impact factor: 5.428

2.  Crowdsourcing sugammadex adverse event rates using an in-app survey: feasibility assessment from an observational study.

Authors:  Craig S Jabaley; Francis A Wolf; Grant C Lynde; Vikas N O'Reilly-Shah
Journal:  Ther Adv Drug Saf       Date:  2018-04-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.